fidelity
发表于 2025-3-23 19:09:47
http://reply.papertrans.cn/43/4263/426222/426222_13.png
FER
发表于 2025-3-24 01:32:52
http://reply.papertrans.cn/43/4263/426222/426222_14.png
aspersion
发表于 2025-3-24 06:07:19
http://reply.papertrans.cn/43/4263/426222/426222_15.png
scrape
发表于 2025-3-24 10:00:31
http://reply.papertrans.cn/43/4263/426222/426222_16.png
漫不经心
发表于 2025-3-24 13:54:22
Mélisande Alberttors have a good antithrombotic effect, with little prolongation of bleeding times, suggesting a larger therapeutic window than currently available antiplatelet drugs. However, at present, none of the collagen receptor blockers are in clinical development yet.
宣誓书
发表于 2025-3-24 18:42:15
Alexandra Carpentier,Jens Eisert,David Gross,Richard Nicklainst VWF-A3; ALX-0081 and ALX-0681, bivalent humanized nanobodies targeting the VWF-A1 domain; ARC1779 and its advanced formulation ARC15105, second-generation aptamers that bind the VWF-A1 domain; h6B4-Fab, a murine monoclonal antibody, and GPG-290, a recombinant chimeric protein, both directed ag
MOAT
发表于 2025-3-24 22:45:25
David Mason,Bruno Pelletieret inhibition results in an increased bleeding risk. Pharmacologic properties and clinical outcome data differ substantially between the existing P2Y12 receptor inhibitors. Whether individualized antiplatelet treatment incorporating different P2Y12 receptor inhibitors improves patients’ clinical out
COLIC
发表于 2025-3-25 01:45:15
http://reply.papertrans.cn/43/4263/426222/426222_20.png
四海为家的人
发表于 2025-3-25 04:34:40
http://reply.papertrans.cn/43/4263/426222/426222_21.png
CT-angiography
发表于 2025-3-25 09:21:20
http://reply.papertrans.cn/43/4263/426222/426222_22.png